Author + information
- Mads Ørbæk Andersen,
- Søren Zöga Diederichsen,
- Jesper Hastrup Svendsen and
- Jorn Carlsen
A few studies to date deploying short-term monitoring (10 minutes-24 hours) have revealed lower heart rate variability (HRV) in patients with pulmonary arterial hypertension (PAH).
In this prospective study, patients were implanted with a Reveal LINQ (Medtronic, Minneapolis, MN, USA) insertable cardiac monitor to monitor HRV, which was expressed as the mean of HRV during all days per patient (SDANN method). Pearson correlations between HRV and established risk determinants were estimated.
Twenty-four patients were included, with 20 having PAH and four having chronic thromboembolic pulmonary hypertension. The follow-up period was 164 patient-months (median: 207 days per patient). Patients' HRV was significantly correlated with the following risk determinants in PH: (1) World Health Organization functional score (WHO FC)(r = −0.8), (2) N-terminal prohormone of brain natriuretic peptide (log-transformed) (r = −0.52), (3) six-minute walking test (r = 0.58), (4) TAPSE (r = 0.52), (5) right ventricular ejection fraction (r = 0.50), and (6) tricuspid regurgitation gradient (r = −0.47).
To our knowledge, this is the first study to apply continuous monitoring of HRV in PH. HRV was significantly correlated with sixmarkers already being used as part of a risk stratification scheme in PH. HRV may contribute to a more efficient non-invasive risk assessment in PH and optimization of treatment.
Moderated Poster Contributions
Congenital Heart Disease and Pulmonary Hypertension Moderated Poster Theater, Posters, Hall A
Saturday, March 28, 2020, 12:45 p.m.-12:55 p.m.
Session Title: A Potpourri of Interesting Topics in Pulmonary Hypertension
Abstract Category: 35. Pulmonary Hypertension
Presentation Number: 1014-05
- 2020 American College of Cardiology Foundation